Menu Search
Equities

BioCardia Inc

BCDA:NAQ

BioCardia Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.31
  • Today's Change0.175 / 8.20%
  • Shares traded25.82k
  • 1 Year change-76.25%
  • Beta1.2422
Data delayed at least 15 minutes, as of Nov 22 2024 18:18 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year BioCardia Inc had revenues fall -64.72% from 1.35m to 477.00k, though the company grew net income from a loss of 11.91m to a smaller loss of 11.57m.
Gross margin--
Net profit margin-10,876.06%
Operating margin-10,935.21%
Return on assets-154.22%
Return on equity-737.89%
Return on investment-401.77%
More ▼

Cash flow in USDView more

In 2023, cash reserves at BioCardia Inc fell by 6.26m. Cash Flow from Financing totalled 3.73m or 781.13% of revenues. In addition the company used 9.97m for operations while cash used for investing totalled 12.00k.
Cash flow per share-3.88
Price/Cash flow per share--
Book value per share0.6086
Tangible book value per share0.6086
More ▼

Balance sheet in USDView more

BioCardia Inc uses little or no debt in its capital structure.
Current ratio1.78
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.